Pfizer Inc. is building on the experience gained during the pandemic, and the unprecedented windfall of profits from its COVID-19 vaccine, to roll out a plan it calls “An Accord for a Healthier World” that will provide current and future patented medications and vaccines on a not-for-profit basis to 45 lower-income countries, beginning with Rwanda, Ghana, Malawi, Uganda and Senegal. CEO Albert Bourla told the World Economic Forum in Davos, Switzerland, on 25 May the initiative will build on what has been learned in providing COVID-19 vaccines globally and address the many obstacles to health care equity in less wealthy nations.
Pfizer To Learn From Pandemic For Health Equity Initiative
The “Accord for a Healthier World” pledges to provide patent-protected medicines on a not-for-profit basis in 45 lower-income nations. Pfizer, which profited most from the COVID-19 pandemic, sees the pandemic experience as a way to advance health equity.
More from Drug Pricing
• By
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.
• By
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
• By
The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."
• By
CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.
More from Scrip
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.